Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Operating Leases (2021 - 2025)

Vivos Therapeutics (VVOS) has disclosed Operating Leases for 5 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases rose 147.5% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.9 million, a 147.5% increase, with the full-year FY2024 number at $1.0 million, down 31.95% from a year prior.
  • Operating Leases was $2.9 million for Q3 2025 at Vivos Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.9 million in Q2 2022 to a low of $641000.0 in Q4 2021.
  • A 5-year average of $1.8 million and a median of $1.8 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 211.08% in 2022, then crashed 50.48% in 2025.
  • Vivos Therapeutics' Operating Leases stood at $641000.0 in 2021, then skyrocketed by 211.08% to $2.0 million in 2022, then dropped by 23.72% to $1.5 million in 2023, then crashed by 31.95% to $1.0 million in 2024, then surged by 176.91% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Operating Leases are $2.9 million (Q3 2025), $2.8 million (Q2 2025), and $932000.0 (Q1 2025).